Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 38


miRNAs associated with prostate cancer risk and progression.

Luu HN, Lin HY, Sørensen KD, Ogunwobi OO, Kumar N, Chornokur G, Phelan C, Jones D, Kidd L, Batra J, Yamoah K, Berglund A, Rounbehler RJ, Yang M, Lee SH, Kang N, Kim SJ, Park JY, Di Pietro G.

BMC Urol. 2017 Mar 20;17(1):18. doi: 10.1186/s12894-017-0206-6. Review.


Transcriptome evaluation of the relation between body mass index and prostate cancer outcomes.

Kim H, Kalchman I, Santiago-Jiménez M, Lehrer J, Guo J, Hermann G, Yamoah K, Alshalalfa M, Huang HC, Ross AE, Schaeffer EM, Davicioni E, Erho N, Yousefi K, Den RB.

Cancer. 2017 Jun 15;123(12):2240-2247. doi: 10.1002/cncr.30580. Epub 2017 Jan 31.


The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy.

Echevarria MI, Naghavi AO, Venkat PS, Abuodeh YA, Chevere C, Yamoah K.

J Contemp Brachytherapy. 2016 Oct;8(5):386-390. Epub 2016 Nov 2.


Predicting Prostate Cancer Recurrence After Radical Prostatectomy.

Jeffers A, Sochat V, Kattan MW, Yu C, Melcon E, Yamoah K, Rebbeck TR, Whittemore AS.

Prostate. 2017 Feb;77(3):291-298. doi: 10.1002/pros.23268. Epub 2016 Oct 24. Erratum in: Prostate. 2017 Jun;77(8):934.


Proton beam therapy: clinical utility and current status in prostate cancer.

Yamoah K, Johnstone PA.

Onco Targets Ther. 2016 Sep 16;9:5721-5727. eCollection 2016. Review.


Treatment delays, race, and outcomes in head and neck cancer.

Naghavi AO, Echevarria MI, Strom TJ, Abuodeh YA, Ahmed KA, Venkat PS, Trotti A, Harrison LB, Green BL, Yamoah K, Caudell JJ.

Cancer Epidemiol. 2016 Dec;45:18-25. doi: 10.1016/j.canep.2016.09.005. Epub 2016 Sep 22.


Having Medicaid insurance negatively impacts outcomes in patients with head and neck malignancies.

Naghavi AO, Echevarria MI, Grass GD, Strom TJ, Abuodeh YA, Ahmed KA, Kim Y, Trotti AM, Harrison LB, Yamoah K, Caudell JJ.

Cancer. 2016 Aug 1. doi: 10.1002/cncr.30212. [Epub ahead of print]


The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer.

Yamoah K, Zeigler-Johnson CM, Jeffers A, Malkowicz B, Spangler E, Park JY, Whittemore A, Rebbeck TR.

BMC Cancer. 2016 Jul 29;16:557. doi: 10.1186/s12885-016-2572-y.


Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials.

Yamoah K, Showalter TN, Ohri N.

Int J Radiat Oncol Biol Phys. 2015 Nov 15;93(4):737-45. doi: 10.1016/j.ijrobp.2015.07.2284. Epub 2015 Oct 19. Review.


Efficient entry of cell-penetrating peptide nona-arginine into adherent cells involves a transient increase in intracellular calcium.

Melikov K, Hara A, Yamoah K, Zaitseva E, Zaitsev E, Chernomordik LV.

Biochem J. 2015 Oct 15;471(2):221-30. doi: 10.1042/BJ20150272. Epub 2015 Aug 13.


Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.

Yamoah K, Johnson MH, Choeurng V, Faisal FA, Yousefi K, Haddad Z, Ross AE, Alshalafa M, Den R, Lal P, Feldman M, Dicker AP, Klein EA, Davicioni E, Rebbeck TR, Schaeffer EM.

J Clin Oncol. 2015 Sep 1;33(25):2789-96. doi: 10.1200/JCO.2014.59.8912. Epub 2015 Jul 20.


Corrigendum: "Training Global Oncologists: Addressing the Global Cancer Control Problem".

Grover S, Balogun OD, Yamoah K, Groen R, Shah M, Rodin D, Martei Y, Olson AC, Slone JS, Shulman LN, Coleman CN, Hahn SM.

Front Oncol. 2015 Jun 10;5:133. doi: 10.3389/fonc.2015.00133. eCollection 2015.


Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.

Palmer JD, Siglin J, Yamoah K, Dan T, Champ CE, Bar-Ad V, Werner-Wasik M, Evans JJ, Kim L, Glass J, Farrell C, Andrews DW, Shi W.

J Neurooncol. 2015 Sep;124(2):215-21. doi: 10.1007/s11060-015-1825-y. Epub 2015 May 30.


Modeled risk of ischemic heart disease following left breast irradiation with deep inspiration breath hold.

Eldredge-Hindy HB, Duffy D, Yamoah K, Simone NL, Skowronski J, Dicker AP, Anne PR.

Pract Radiat Oncol. 2015 May-Jun;5(3):162-8. doi: 10.1016/j.prro.2014.10.002.


Training global oncologists: addressing the global cancer control problem.

Grover S, Balogun OD, Yamoah K, Groen R, Shah M, Rodin D, Olson AC, Slone JS, Shulman LN, Coleman CN, Hahn SM.

Front Oncol. 2015 Apr 8;5:80. doi: 10.3389/fonc.2015.00080. eCollection 2015. Review. No abstract available. Erratum in: Front Oncol. 2015;5:133.


African-american race is a predictor of seminal vesicle invasion after radical prostatectomy.

Yamoah K, Walker A, Spangler E, Zeigler-Johnson CM, Malkowicz B, Lee DI, Dicker AP, Rebbeck TR, Lal P.

Clin Genitourin Cancer. 2015 Apr;13(2):e65-72. doi: 10.1016/j.clgc.2014.08.012. Epub 2014 Oct 25.


African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men.

Yamoah K, Deville C, Vapiwala N, Spangler E, Zeigler-Johnson CM, Malkowicz B, Lee DI, Kattan M, Dicker AP, Rebbeck TR.

Urol Oncol. 2015 Feb;33(2):70.e15-22. doi: 10.1016/j.urolonc.2014.07.005. Epub 2014 Oct 7.


Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma.

Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB.

Brachytherapy. 2014 Sep-Oct;13(5):456-64. doi: 10.1016/j.brachy.2014.04.003. Epub 2014 Jun 18.


A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.

Zaorsky NG, Yamoah K, Thakur ML, Trabulsi EJ, Showalter TN, Hurwitz MD, Dicker AP, Den RB.

Future Oncol. 2014 Feb;10(3):457-74. doi: 10.2217/fon.13.196. Review.


High dose rate brachytherapy boost for prostate cancer: a systematic review.

Zaorsky NG, Doyle LA, Yamoah K, Andrel JA, Trabulsi EJ, Hurwitz MD, Dicker AP, Den RB.

Cancer Treat Rev. 2014 Apr;40(3):414-25. doi: 10.1016/j.ctrv.2013.10.006. Epub 2013 Oct 26. Review.


Supplemental Content

Loading ...
Support Center